Published in J Interferon Cytokine Res on March 18, 2013
Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host. Biology (Basel) (2013) 0.86
Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies. Front Oncol (2014) 0.83
Bortezomib attenuates HIF-1- but not HIF-2-mediated transcriptional activation. Oncol Lett (2015) 0.78
Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate! Biomedicines (2016) 0.77
Oncolytic virotherapy for urological cancers. Nat Rev Urol (2016) 0.76
Newcastle disease virus degrades HIF-1α through proteasomal pathways independent of VHL and p53. J Gen Virol (2016) 0.76
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
Hypoxia-inducible factors in physiology and medicine. Cell (2012) 8.16
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer (2011) 6.32
A road map for those who don't know JAK-STAT. Science (2002) 5.67
Tumour suppression by the human von Hippel-Lindau gene product. Nat Med (1995) 4.71
TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat Immunol (2002) 4.63
Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer (2004) 4.43
The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer (2008) 4.42
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med (2000) 4.37
The JAK/STAT signaling pathway. J Cell Sci (2004) 4.23
Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood (1998) 3.67
Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci (1994) 3.36
Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res (2010) 2.88
The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem (1998) 2.13
Hypoxia inducible factor-2alpha in cancer. Cell Cycle (2007) 1.90
Major DNA fragmentation is a late event in apoptosis. J Histochem Cytochem (1997) 1.77
Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res (2001) 1.73
Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol (2000) 1.61
Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol (2006) 1.44
NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT. Cancer (1965) 1.43
2009 update on the classification of renal epithelial tumors in adults. Int J Urol (2009) 1.43
Newcastle disease virus selectively kills human tumor cells. J Surg Res (1992) 1.40
Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles. Viruses (2010) 1.30
Molecular aspects of renal cell carcinoma: a review. Am J Cancer Res (2010) 1.25
Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol Biol (2009) 1.17
Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol (2006) 1.15
IFN-beta induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Oncogene (2000) 1.14
Adenosine A2A receptor is a unique angiogenic target of HIF-2alpha in pulmonary endothelial cells. Proc Natl Acad Sci U S A (2009) 1.12
Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J Virol (2011) 1.12
Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo. J Virol (2004) 1.10
Hypoxic repression of STAT1 and its downstream genes by a pVHL/HIF-1 target DEC1/STRA13. Oncogene (2006) 1.09
Newcastle disease virus: macromolecules and opportunities. Avian Pathol (2001) 1.09
Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer (2006) 1.08
Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy. J Virol (2010) 1.07
The suppressors of cytokine signalling (SOCS). Cell Mol Life Sci (2001) 1.06
SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res (2007) 1.04
Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother (1994) 0.99
Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: role of HIF in antiviral response. J Virol (2006) 0.93
Sequence of the haemagglutinin-neuraminidase gene of the Newcastle disease virus oral vaccine strain V4(UPM). Avian Pathol (1996) 0.91
Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus. EMBO Mol Med (2010) 0.90
Cytolytic effects and apoptosis induction of Newcastle disease virus strain AF2240 on anaplastic astrocytoma brain tumor cell line. Neurochem Res (2011) 0.90
Beta interferon-mediated activation of signal transducer and activator of transcription protein 1 interferes with Rickettsia conorii replication in human endothelial cells. Infect Immun (2011) 0.86
Effects of newcastle disease virus strains AF2240 and V4-UPM on cytolysis and apoptosis of leukemia cell lines. Int J Mol Sci (2011) 0.85
Time-course induction of apoptosis by wild-type and attenuated strains of rubella virus. J Gen Virol (2003) 0.81
Molecularly targeted agents for renal cell carcinoma: the next generation. Clin Adv Hematol Oncol (2010) 0.81
Reduced Newcastle disease virus-induced oncolysis in a subpopulation of cisplatin-resistant MCF7 cells is associated with survivin stabilization. Cancer Cell Int (2012) 0.79
Type I interferon resistance in a colorectal cancer cell line is associated with a more aggressive phenotype in vivo. Br J Cancer (1992) 0.76
Isolation and molecular identification of Nipah virus from pigs. Emerg Infect Dis (2004) 2.59
Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res (2008) 2.29
Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? Biochim Biophys Acta (2009) 1.55
Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol (2004) 1.42
Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res (2005) 1.41
TSLC1 is a tumor suppressor gene associated with metastasis in nasopharyngeal carcinoma. Cancer Res (2006) 1.35
Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3'-kinase. Cancer Res (2002) 1.35
Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain. Mol Cell Biol (2006) 1.34
DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. Mol Cell Biol (2004) 1.22
THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma. Oncogene (2005) 1.12
Regulation of gene expression by hypoxia: integration of the HIF-transduced hypoxic signal at the hypoxia-responsive element. Clin Chim Acta (2008) 1.10
Outlook of dengue in Malaysia: a century later. Malays J Pathol (2002) 1.09
Tumor suppressive role of a 2.4 Mb 9q33-q34 critical region and DEC1 in esophageal squamous cell carcinoma. Oncogene (2005) 1.08
Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia-responsive enhancer. Cancer Res (2003) 1.08
Alternative mRNA splicing of liver intestine-cadherin in hepatocellular carcinoma. Clin Cancer Res (2005) 1.07
Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma. Cancer Res (2008) 1.07
Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection. Cancer Res (2003) 1.04
PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. Cancer Lett (2009) 1.04
Rational design of minimal hypoxia-inducible enhancers. Biochem Biophys Res Commun (2008) 1.03
ATR dependent activation of Chk2. J Cell Physiol (2006) 1.03
Cysteine-rich intestinal protein 2 (CRIP2) acts as a repressor of NF-kappaB-mediated proangiogenic cytokine transcription to suppress tumorigenesis and angiogenesis. Proc Natl Acad Sci U S A (2011) 0.99
A quantitative single-cell assay for protein kinase B reveals important insights into the biochemical behavior of an intracellular substrate peptide. Biochemistry (2004) 0.98
Recombinant Newcastle Disease virus capsids displaying enterovirus 71 VP1 fragment induce a strong immune response in rabbits. J Med Virol (2006) 0.97
Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype. Int J Cancer (2011) 0.97
Expression of hypoxia-inducible carbonic anhydrases in brain tumors. Neuro Oncol (2005) 0.97
Expression of transmembrane carbonic anhydrases, CAIX and CAXII, in human development. BMC Dev Biol (2009) 0.97
Characterization of a novel epigenetically-silenced, growth-suppressive gene, ADAMTS9, and its association with lymph node metastases in nasopharyngeal carcinoma. Int J Cancer (2008) 0.96
Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis. Cancer Res (2010) 0.95
Catalytic activity of Matrix metalloproteinase-19 is essential for tumor suppressor and anti-angiogenic activities in nasopharyngeal carcinoma. Int J Cancer (2011) 0.95
CADM1 interacts with Tiam1 and promotes invasive phenotype of human T-cell leukemia virus type I-transformed cells and adult T-cell leukemia cells. J Biol Chem (2010) 0.94
Functional studies of the chromosome 3p21.3 candidate tumor suppressor gene BLU/ZMYND10 in nasopharyngeal carcinoma. Int J Cancer (2006) 0.94
Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States. Int J Cancer (2009) 0.93
Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol (2009) 0.93
Identification and characterisation of a novel anti-viral peptide against avian influenza virus H9N2. Virol J (2009) 0.92
Successful transfer of plasmid DNA into in vitro cells transfected with an inorganic plasmid-Mg/Al-LDH nanobiocomposite material as a vector for gene expression. Nanotechnology (2008) 0.92
The ECM protein LTBP-2 is a suppressor of esophageal squamous cell carcinoma tumor formation but higher tumor expression associates with poor patient outcome. Int J Cancer (2010) 0.92
Anti-leukemic activity of Newcastle disease virus strains AF2240 and V4-UPM in murine myelomonocytic leukemia in vivo. Leuk Res (2011) 0.92
The role of extracellular signal-regulated protein kinase in transcriptional regulation of the hypoxia marker carbonic anhydrase IX. J Cell Biochem (2006) 0.92
Lactobacillus acidophilus as a live vehicle for oral immunization against chicken anemia virus. Appl Microbiol Biotechnol (2010) 0.91
Melatonin mt1 and MT2 receptors stimulate c-Jun N-terminal kinase via pertussis toxin-sensitive and -insensitive G proteins. Cell Signal (2002) 0.91
Sequence and phylogenetic analysis of Newcastle disease virus genotypes isolated in Malaysia between 2004 and 2005. Arch Virol (2009) 0.90
Functional characterization of THY1 as a tumor suppressor gene with antiinvasive activity in nasopharyngeal carcinoma. Int J Cancer (2010) 0.90
Cytolytic effects and apoptosis induction of Newcastle disease virus strain AF2240 on anaplastic astrocytoma brain tumor cell line. Neurochem Res (2011) 0.90
Characterization of TAT-mediated transport of detachable kinase substrates. Biochemistry (2004) 0.89
Inactivation of the cystatin E/M tumor suppressor gene in cervical cancer. Genes Chromosomes Cancer (2008) 0.89
Does inhibition of degradation of hypoxia-inducible factor (HIF) alpha always lead to activation of HIF? Lessons learnt from the effect of proteasomal inhibition on HIF activity. J Cell Biochem (2008) 0.89
Fine mapping of the 11q22-23 tumor suppressive region and involvement of TSLC1 in nasopharyngeal carcinoma. Int J Cancer (2004) 0.89
Localization of deletion to a 300 Kb interval of chromosome 11q13 in cervical cancer. Oncogene (2002) 0.89
Newcastle disease virus nucleocapsid protein: self-assembly and length-determination domains. J Gen Virol (2003) 0.88
Chromosome 14 transfer and functional studies identify a candidate tumor suppressor gene, mirror image polydactyly 1, in nasopharyngeal carcinoma. Proc Natl Acad Sci U S A (2009) 0.88
Selection of high affinity ligands to hepatitis B core antigen from a phage-displayed cyclic peptide library. J Med Virol (2003) 0.87
Safety and clinical usage of newcastle disease virus in cancer therapy. J Biomed Biotechnol (2011) 0.87
Newcastle disease virus infection promotes Bax redistribution to mitochondria and cell death in HeLa cells. Intervirology (2009) 0.87
Expression of candidate chromosome 3p21.3 tumor suppressor genes and down-regulation of BLU in some esophageal squamous cell carcinomas. Cancer Lett (2006) 0.86
Deciphering the molecular genetic basis of NPC through functional approaches. Semin Cancer Biol (2011) 0.86
Mapping of nasopharyngeal carcinoma tumor-suppressive activity to a 1.8-megabase region of chromosome band 11q13. Genes Chromosomes Cancer (2002) 0.86
A novel peptide inhibits the influenza virus replication by preventing the viral attachment to the host cells. Int J Biol Sci (2009) 0.85
Functional evidence of decreased tumorigenicity associated with monochromosome transfer of chromosome 14 in esophageal cancer and the mapping of tumor-suppressive regions to 14q32. Genes Chromosomes Cancer (2005) 0.84
The LIM domain protein, CRIP2, promotes apoptosis in esophageal squamous cell carcinoma. Cancer Lett (2011) 0.84
Monochromosome transfer and microarray analysis identify a critical tumor-suppressive region mapping to chromosome 13q14 and THSD1 in esophageal carcinoma. Mol Cancer Res (2008) 0.84
Monochromosome transfer provides functional evidence for growth-suppressive genes on chromosome 14 in nasopharyngeal carcinoma. Genes Chromosomes Cancer (2003) 0.84
Overexpressing 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) in the lactococcal mevalonate pathway for heterologous plant sesquiterpene production. PLoS One (2012) 0.84
Mutagenesis of the nucleocapsid protein of Nipah virus involved in capsid assembly. J Gen Virol (2009) 0.84
The matrix (M) protein of Newcastle disease virus binds to human bax through its BH3 domain. Virol J (2011) 0.83
Purification and characterization of Nipah virus nucleocapsid protein produced in insect cells. J Clin Microbiol (2005) 0.83
Solubility, immunogenicity and physical properties of the nucleocapsid protein of Nipah virus produced in Escherichia coli. J Med Virol (2004) 0.83
Molecular genetic analysis of BAX and cyclin D1 genes in patients with malignant glioma. Neurol Res (2007) 0.83
Detection and differentiation of velogenic and lentogenic Newcastle disease viruses using SYBR Green I real-time PCR with nucleocapsid gene-specific primers. J Virol Methods (2009) 0.83
Hypoxia affects cellular responses to plant extracts. J Ethnopharmacol (2012) 0.83
LTBP-2 confers pleiotropic suppression and promotes dormancy in a growth factor permissive microenvironment in nasopharyngeal carcinoma. Cancer Lett (2012) 0.83
DNA vaccine encoding avian influenza virus H5 and Esat-6 of Mycobacterium tuberculosis improved antibody responses against AIV in chickens. Comp Immunol Microbiol Infect Dis (2009) 0.83
Partial protection against enterovirus 71 (EV71) infection in a mouse model immunized with recombinant Newcastle disease virus capsids displaying the EV71 VP1 fragment. J Med Virol (2011) 0.82
Mapping of a single locus capable of complementing the defective heterochromatin phenotype of Roberts syndrome cells. Am J Hum Genet (2005) 0.82
Development of a DNA vaccine against chicken anemia virus by using a bicistronic vector expressing VP1 and VP2 proteins of CAV. Comp Immunol Microbiol Infect Dis (2010) 0.82
p53-dependent Chk1 phosphorylation is required for maintenance of prolonged G2 Arrest. Radiat Res (2007) 0.82
Improving the potency of DNA vaccine against chicken anemia virus (CAV) by fusing VP1 protein of CAV to Marek's Disease Virus (MDV) type-1 VP22 protein. Virol J (2011) 0.81
Antigenicity and immunogenicity of the immunodominant region of hepatitis B surface antigen displayed on bacteriophage T7. J Med Virol (2005) 0.81
Complexity of the mechanisms of initiation and maintenance of DNA damage-induced G2-phase arrest and subsequent G1-phase arrest: TP53-dependent and TP53-independent roles. Radiat Res (2003) 0.81
Display of hepatitis B virus PreS1 peptide on bacteriophage T7 and its potential in gene delivery into HepG2 cells. J Virol Methods (2009) 0.81
Identification of epitopes in the nucleocapsid protein of Nipah virus using a linear phage-displayed random peptide library. J Med Virol (2005) 0.81
Mitogen-activated protein/extracellular signal-regulated kinase kinase 1act/tubulin interaction is an important determinant of mitotic stability in cultured HT1080 human fibrosarcoma cells. Cancer Res (2010) 0.80
Detection and phylogenetic profiling of nodavirus associated with white tail disease in Malaysian Macrobrachium rosenbergii de Man. Mol Biol Rep (2012) 0.80
Comment on the role of FIH in the inhibitory effect of bortezomib on hypoxia-inducible factor-1. Blood (2008) 0.80
Functional expression of an orchid fragrance gene in Lactococcus lactis. Int J Mol Sci (2012) 0.80
Cloning and in silico characterization of two signal peptides from Pediococcus pentosaceus and their function for the secretion of heterologous protein in Lactococcus lactis. Biotechnol Lett (2012) 0.79
Tumour suppressive effects of WEE1 gene silencing in breast cancer cells. Asian Pac J Cancer Prev (2014) 0.79
Lactococcus lactis M4, a potential host for the expression of heterologous proteins. Microb Cell Fact (2011) 0.79
Cloning and expression of the nucleocapsid protein gene of nipah virus in different strains of Escherichia coli. J Biochem Mol Biol Biophys (2002) 0.79
Reduced Newcastle disease virus-induced oncolysis in a subpopulation of cisplatin-resistant MCF7 cells is associated with survivin stabilization. Cancer Cell Int (2012) 0.79
Identification of tumor suppressive activity by irradiation microcell-mediated chromosome transfer and involvement of alpha B-crystallin in nasopharyngeal carcinoma. Int J Cancer (2008) 0.79
Characterization of Malaysian velogenic NDV strain AF2240-I genomic sequence: a comparative study. Virus Genes (2013) 0.79
Detection of virulent Newcastle disease virus using a phage-capturing dot blot assay. J Virol Methods (2006) 0.78
Comparative evaluation of three purification methods for the nucleocapsid protein of Newcastle disease virus from Escherichia coli homogenates. J Microbiol (2005) 0.78